Variant of ETV6/ABL1 gene is associated with leukemia phenotype

Acta Haematologica

Volumn 129, Issue 2, 2013, Pages 78-82

  Park, Joonhong ^a,b   Kim, Myungshin ^a,b   Lim, Jihyang ^a,b   Kim, Yonggoo ^a,b   Han, Kyungja ^a,b   Kim, Jae Seok ^b   Lee, Seok ^b   Kim, Hee Je ^b   Min, Woo Sung ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Cryptic insertion; Eosinophilia; ETV6 ABL1 fusion; Exon 5 of ETV6

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; HLA DR ANTIGEN; LACTATE DEHYDROGENASE; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; MYELOPEROXIDASE; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR ETV6; VINCRISTINE; WT1 PROTEIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FLT3 LIGAND; NUCLEOPHOSMIN; STEM CELL FACTOR; ONCOPROTEIN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ETS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BASOPHIL; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CONSOLIDATION CHEMOTHERAPY; DISEASE DURATION; DISEASE SEVERITY; EOSINOPHIL; EOSINOPHILIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; GENE PROBE; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; LYMPHOBLAST; LYMPHOCYTE; MALE; MONOCYTE; MULTIMODALITY CANCER THERAPY; MYELOBLAST; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; CANCER REGRESSION; CELL INFILTRATION; COUGHING; CYTOGENETICS; ETV6 ABL1 FUSION GENE; EXON; FUSION GENE; GENE DUPLICATION; GENETIC VARIABILITY; HUMAN CELL; LEUKOCYTOSIS; METAPHASE; MIDDLE AGED; MYALGIA; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPTIC SHOCK; FATALITY; GENE TRANSLOCATION; GENETICS; ONCOGENE;

ADULT; EOSINOPHILIA; FATAL OUTCOME; FEMALE; GENES, ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

MLCS; MLOWN;

EID: 84869208759     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000342490     Document Type: Article

References (32)

1. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM: The novel activation of ABL by fusion to an ETS-related gene, TEL. Cancer Res 1995; 55: 34-38.
2. Brunel V, Sainty D, Carbuccia N, Mozzicconacci M, Fernandez F, Simonetti J, Gabert J, Dubreuil P, Lafage-Pochitaloff M, Birg F: A TEL/ABL fusion gene on chromosome 12p13 in a case of Ph-, BCR-atypical CML. Leukemia 1996; 10: 2003.
3. Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Höglund M: BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 1997; 20: 299-304. (Pubitemid 27484106)
4. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hählen K, Poppe B, Van Roy N, Marynen P, De Paepe A, Slater R, Speleman F: Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001; 30: 274-282. (Pubitemid 32126204)
5. Lin H, Guo JQ, Andreeff M, Arlinghaus RB: Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 2002; 16: 294-297. (Pubitemid 34145148)
6. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M: Chronic myelocytic leukemia with eosinophilia, t(9; 12) (q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet 2002; 138: 139-142. (Pubitemid 36020469)
7. Barbouti A, Ahlgren T, Johansson B, Höglund M, Lassen C, Turesson I, Mitelman F, Fioretos T: Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol 2003; 122: 85-93. (Pubitemid 36819342)
8. Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman BK: Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet 2005; 157: 74-77. (Pubitemid 40164863)
9. Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S: Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer 2008; 47: 919-921.
10. Kelly JC, Shahbazi N, Scheerle J, Jahn J, Suchen S, Christacos NC, Mowrey PN, Witt MH, Hostetter A, Meloni-Ehrig AM: Insertion (12; 9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet 2009; 192: 36-39.
11. Meyer-Monard S, Mühlematter D, Streit A, Chase AJ, Gratwohl A, Cross NC, Jotterand M, Tichelli A: Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia 2005; 19: 1096-1099. (Pubitemid 40862029)
12. Mozziconacci MJ, Sainty D, Chabannon C: A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome. Am J Hematol 2007; 82: 688-689. (Pubitemid 47015309)
13. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E: Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009; 33: 1144-1146.
14. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG: Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996; 16: 4107-4116. (Pubitemid 26251210)
15. O'Brien SG, Vieira SA, Connors S, Bown N, Chang J, Capdeville R, Melo JV: Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9; 12) translocation. Blood 2002; 99: 3465-3467. (Pubitemid 34525333)
16. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, Flandrin G, Pelicci PG, Mecucci C: Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 2002; 87: 789-794. (Pubitemid 34851547)
17. Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA: Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet 2008; 185: 37-42.
18. Zuna J, Zaliova M, Muzikova K, Meyer C, Lizcova L, Zemanova Z, Brezinova J, Votava F, Marschalek R, Stary J, Trka J: Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer 2010; 49: 873-884.
19. Hannemann JR, McManus DM, Kabarowski JH, Wiedemann LM: Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol 1998; 102: 475-485. (Pubitemid 28346589)
20. Million RP, Aster J, Gilliland DG, Van Etten RA: The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9; 12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 2002; 99: 4568-4577. (Pubitemid 34627229)
21. Okuda K, Golub TR, Gilliland DG, Griffin JD: p210 BCR/ABL, p190 BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 1996; 13: 1147-1152. (Pubitemid 26343567)
22. Malinge S, Monni R, Bernard O, Penard-Lacronique V: Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 2006; 25: 3589-3597. (Pubitemid 43901680)
23. Pecquet C, Nyga R, Penard-Lacronique V, Smithgall TE, Murakami H, Régnier A, Lassoued K, Gouilleux F: The Src tyrosine kinase Hck is required for Tel-Abl-but not for Tel-Jak2-induced cell transformation. Oncogene 2007; 26: 1577-1585. (Pubitemid 46398735)
24. Shaffer LG, Slovak ML, Campbell LJ: ISCN 2009. An International System for Human Cytogenetic Nomenclature. Basel, Karger, 2009.
25. Bohlander SK: Fusion genes in leukemia: an emerging network. Cytogenet Cell Genet 2000; 91: 52-56. (Pubitemid 32110340)
26. Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD: Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 2001; 31: 134-142. (Pubitemid 32411039)
27. Tosi S, Hughes J, Scherer SW, Nakabayashi K, Harbott J, Haas OA, Cazzaniga G, Biondi A, Kempski H, Kearney L: Heterogeneity of the 7q36 breakpoints in the t(7; 12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2003; 38: 191-200. (Pubitemid 37093437)
28. Zhou MH, Gao L, Jing Y, Xu YY, Ding Y, Wang N, Wang W, Li MY, Han XP, Sun JZ, Wang LL, Yu L: Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol 2012; 91: 1235-1243.
29. Park J, Kim M, Lim J, Kim Y, Han K, Lee J, Chung NG, Cho B, Kim HK: Three-way complex translocations in infant acute myeloid leukemia with t(7; 12)(q36;p13): the incidence and correlation of a HLXB9 overexpression. Cancer Genet Cytogenet 2009; 19: 102-105.
30. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA: A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 2004; 24: 4685-4695. (Pubitemid 38668036)
31. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TELPDGFR fusion proteins. Blood 1997; 90: 4947-4952. (Pubitemid 28007210)
32. Okuda K, Weisberg E, Gilliland DG, Griffin JD: ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440-2448. (Pubitemid 32291492)